Isabela Busnello de Souza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Isabela Busnello de Souza has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Giovanna Leal Klein Renz
Federal University of Parana, Curitiba, Brazil
2 shared publications - Laurindo Moacir Sassi
Hospital Erasto Gaertner, Curitiba, Brazil
2 shared publications - Luciana Almeida Lopes
Nupen Institute, São Carlos, Brazil
2 shared publications - Melissa Rodrigues de Araujo
Federal University of Parana, Curitiba, Brazil
2 shared publications - Waleska Tychanowicz Kolodziejwski
Federal University of Parana, Curitiba, Brazil
2 shared publications - Maria Luisa Franceschi Coimbra
Federal University of Parana, Curitiba, Brazil
1 shared publication
Latest Publications
- Open Access
- 29 July 2026
- Published by Springer Nature in Lasers in Medical Science
- Vol. 41 (1) , 172
Comparative efficacy of two photobiomodulation protocols transcutaneous versus intraoral in the prevention of oral mucositis in head and neck cancer: a randomized study protocol
This study aims to compare the clinical efficacy of transcutaneous photobiomodulation (PBMT) with an 808 nm infrared laser versus intraoral PBMT with a 660 nm red laser in the prevention of oral mucositis (OM). The study is designed to assess whether the transcutaneous approach is non-inferior to the intraoral standard, thereby contributing to the optimization and standardization of PBMT protocols in head and neck cancer (HNC) supportive care. Methods: A randomized pilot study is being conducted with 54 patients ( n = 27 per group) undergoing radiotherapy (60–70 Gy) for HNC. Participants will be randomly assigned to receive either intraoral PBMT (660 nm, 100 mW, 1 J/point, fluence = 10.20 J/ cm², 10 s, 44 points) or transcutaneous PBMT (808 nm, 100 mW, 1 J/point, fluence = 34.5 J/ cm² (central) and 4.3 J/ cm² (lateral), 10 s, 32 points). Interventions occur three times weekly throughout treatment. The primary outcome is OM severity, graded by WHO scale. Secondary outcomes include OM severity (NCI-CTCAE), pain intensity (Numeric Rating Scale, NRS), ulcerated area extension, registered through digital images, treatment interruptions and unscheduled healthcare utilization. Expected outcomes: the primary hypothesis posits that transcutaneous infrared PBMT is as effective as intraoral red PBMT in mitigating OM severity. Additionally, the transcutaneous approach is expected to offer logistical advantages, including a reduction in application time (80 s vs. 440 s) and improved tolerability in patients with radiation-induced trismus or severe oral pain. Conclusion: This protocol is expected to provide robust evidence to support the most feasible and effective PBMT modality for OM prevention. By optimizing treatment delivery, the study may enhance adherence, preserve nutritional status, and improve the quality of life for patients undergoing oncological therapy.
- 29 July 2026
- Published by Springer Nature in Lasers in Medical Science
- Vol. 41 (1) , 172
Open AccessComparative efficacy of two photobiomodulation protocols transcutaneous versus intraoral in the prevention of oral mucositis in head and neck cancer: a randomized study protocol
This study aims to compare the clinical efficacy of transcutaneous photobiomodulation (PBMT) with an 808 nm infrared laser versus intraoral PBMT with a 660 nm red laser in the prevention of oral mucositis (OM). The study is designed to assess whether the transcutaneous approach is non-inferior to the intraoral standard, thereby contributing to the optimization and standardization of PBMT protocols in head and neck cancer (HNC) supportive care. Methods: A randomized pilot study is being conducted with 54 patients ( n = 27 per group) undergoing radiotherapy (60–70 Gy) for HNC. Participants will be randomly assigned to receive either intraoral PBMT (660 nm, 100 mW, 1 J/point, fluence = 10.20 J/ cm², 10 s, 44 points) or transcutaneous PBMT (808 nm, 100 mW, 1 J/point, fluence = 34.5 J/ cm² (central) and 4.3 J/ cm² (lateral), 10 s, 32 points). Interventions occur three times weekly throughout treatment. The primary outcome is OM severity, graded by WHO scale. Secondary outcomes include OM severity (NCI-CTCAE), pain intensity (Numeric Rating Scale, NRS), ulcerated area extension, registered through digital images, treatment interruptions and unscheduled healthcare utilization. Expected outcomes: the primary hypothesis posits that transcutaneous infrared PBMT is as effective as intraoral red PBMT in mitigating OM severity. Additionally, the transcutaneous approach is expected to offer logistical advantages, including a reduction in application time (80 s vs. 440 s) and improved tolerability in patients with radiation-induced trismus or severe oral pain. Conclusion: This protocol is expected to provide robust evidence to support the most feasible and effective PBMT modality for OM prevention. By optimizing treatment delivery, the study may enhance adherence, preserve nutritional status, and improve the quality of life for patients undergoing oncological therapy.
- Open Access
- 30 March 2026
- Published by Springer Nature in Lasers in Dental Science
- Vol. 10 (1) , 15
Intraoral and transcutaneous photobiomodulation protocol for hyposalivation in head and neck cancer patients undergoing radiotherapy: a study protocol
Introduction: Hyposalivation is a common complication in patients undergoing head and neck radiotherapy. It negatively affects quality of life and increases the risk of secondary conditions such as dental caries, opportunistic infections, and nutritional impairment. Photobiomodulation (PBM) has been proposed as a preventive strategy; however, there is no consensus regarding the optimal protocol or the most appropriate route of application. Methods: This pilot study aims to compare the efficacy of intraoral and transcutaneous PBM in preventing radiotherapy-induced hyposalivation. The intraoral protocol will use a 660 nm red laser (100 mW, 1 J, 10 s per point, 10.02 J/cm², total 44 points). The transcutaneous protocol will use an 808 nm infrared laser (100 mW, 1 J, 10 s per point, total 32 points). The intraoral approach will deliver targeted irradiation to oral tissues, while the transcutaneous approach will deliver infrared irradiation externally, taking advantage of its greater tissue penetration and potentially improved patient comfort. Outcomes: The primary outcome will be the incidence of stimulated salivary flow rate (salivary flow rate < 0.7 mL/min). Secondary outcomes will include patient-reported xerostomia and quality of life, assessed using validated instruments. Conclusions: This study will provide comparative data on two PBM delivery approaches for the prevention of radiotherapy-induced hyposalivation and may contribute to the optimization of clinical protocols in oncological care.
- 30 March 2026
- Published by Springer Nature in Lasers in Dental Science
- Vol. 10 (1) , 15
Open AccessIntraoral and transcutaneous photobiomodulation protocol for hyposalivation in head and neck cancer patients undergoing radiotherapy: a study protocol
Introduction: Hyposalivation is a common complication in patients undergoing head and neck radiotherapy. It negatively affects quality of life and increases the risk of secondary conditions such as dental caries, opportunistic infections, and nutritional impairment. Photobiomodulation (PBM) has been proposed as a preventive strategy; however, there is no consensus regarding the optimal protocol or the most appropriate route of application. Methods: This pilot study aims to compare the efficacy of intraoral and transcutaneous PBM in preventing radiotherapy-induced hyposalivation. The intraoral protocol will use a 660 nm red laser (100 mW, 1 J, 10 s per point, 10.02 J/cm², total 44 points). The transcutaneous protocol will use an 808 nm infrared laser (100 mW, 1 J, 10 s per point, total 32 points). The intraoral approach will deliver targeted irradiation to oral tissues, while the transcutaneous approach will deliver infrared irradiation externally, taking advantage of its greater tissue penetration and potentially improved patient comfort. Outcomes: The primary outcome will be the incidence of stimulated salivary flow rate (salivary flow rate < 0.7 mL/min). Secondary outcomes will include patient-reported xerostomia and quality of life, assessed using validated instruments. Conclusions: This study will provide comparative data on two PBM delivery approaches for the prevention of radiotherapy-induced hyposalivation and may contribute to the optimization of clinical protocols in oncological care.